Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study

In recent years the use of immunomodulating therapy to treat various cancers has been on the rise. Three checkpoint inhibitors have been approved by the Food and Drug Administration (ipilimumab, pembrolizumab and nivolumab). The use of these drugs comes with serious adverse events related to excessi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bajwa, Ravneet, Cheema, Anmol, Khan, Taimoor, Amirpour, Alireza, Paul, Anju, Chaughtai, Saira, Patel, Shrinil, Patel, Tejas, Bramson, Joshua, Gupta, Varsha, Levitt, Michael, Asif, Arif, Hossain, Mohammad A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436564/
https://www.ncbi.nlm.nih.gov/pubmed/30937112
http://dx.doi.org/10.14740/jocmr3750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436564/
https://www.ncbi.nlm.nih.gov/pubmed/30937112
http://dx.doi.org/10.14740/jocmr3750

Ejemplares similares